Will Genmab report Q2 2026 revenue above its Q1 2026 revenue? NordCast market: Yes 53% · No 48% · Denmark Earnings · Vol DKK 1.1M · Closes Aug 7 · Source: Genmab Q1 2026 report.
This market resolves Yes if the event in "Will Genmab report Q2 2026 revenue above its Q1 2026 revenue?" happens according to the listed rule and source. Otherwise it resolves No.
Genmab Q1 2026 report should be checked first for final settlement. Major news reporting can move the market before settlement, but the final result should be traceable to the official source.
Earnings markets should resolve from the company report itself, using the line item named in the market question rather than commentary about whether the quarter was good or bad.
It asks whether the outcome in "Will Genmab report Q2 2026 revenue above its Q1 2026 revenue?" resolves Yes or No before the listed close date.
The market should resolve using Genmab Q1 2026 report as the primary settlement source. News can provide context, but the final outcome should be auditable from the source rule.
NordCast prices are shown as probability-style points from 0 to 100. A Yes price of 53% means the market is currently implying roughly a 53% chance of Yes.